FDA Accepts Supplement Application for Zoledronic Acid by Mylan Labs
The FDA has accepted the supplemental application ANDA205254 for Zoledronic Acid submitted by Mylan Labs.
Company
Pharmaceutical intelligence for Mylan Labs with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.